Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.74 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.73 |
| ▸ | BCHE | P06276 | 3/20 | 0.64 |
| ▸ | MAOB | P27338 | 5/20 | 0.62 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.62 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.59 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29462055 | 1.00 | CYP4F2 (0.74) | CYP4F2CYP4A11TSHRSMN1; SMN2BCHE | |
| SCHEMBL27736763 | 0.89 | SMN1; SMN2 (0.65) | CYP4F2CYP4A11TSHRSMN1; SMN2BCHE | |
| SCHEMBL29961933 | 0.89 | TSHR (0.59) | CYP4F2CYP4A11TSHRSMN1; SMN2MAOB | |
| SCHEMBL28893553 | 0.89 | TSHR (0.59) | CYP4F2CYP4A11TSHRSMN1; SMN2MAOB | |
| SCHEMBL3271153 | 0.86 | CYP4F2 (0.61) | CYP4F2CYP4A11TSHRSMN1; SMN2BCHE | |
| SCHEMBL4910012 | 0.86 | MEN1 (0.62) | CYP4F2CYP4A11TSHRSMN1; SMN2BCHE | |
| SCHEMBL11121827 | 0.86 | SMN1; SMN2 (0.66) | CYP4F2CYP4A11TSHRSMN1; SMN2MAOB | |
| SCHEMBL15761340 | 0.86 | BCHE (0.70) | CYP4F2CYP4A11SMN1; SMN2BCHEMAOB | |
| SCHEMBL1268719 | 0.86 | MAOB (0.81) | CYP4F2CYP4A11BCHEMAOBNR4A2 | |
| SCHEMBL3179250 | 0.85 | CYP4F2 (1.00) | CYP4F2CYP4A11TSHRSMN1; SMN2BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 353 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6989052-B1 | Phase change ink printing process | XEROX CORPORATION (US) | 2006-01-24 | — | — | US | claimed |
| US-20060004123-A1 | PHASE CHANGE INK PRINTING PROCESS | XEROX CORPORATION | 2006-01-05 | — | — | US | claimed |
| EP-1575495-A2 | COMPOUNDS AND METHODS | SmithKline Beecham Corporation (US) | 2005-09-21 | — | — | EP | claimed |
| WO-2003082205-A2 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-09 | — | — | WO | claimed |
| US-6319310-B1 | FOR ACOUSTIC INK JET PRINTING; TRANSPARENCY, GLOSS, CREASE RESISTANCE | XEROX CORPORATION | 2001-11-20 | — | — | US | claimed |
| EP-0674232-B1 | Recording sheets | XEROX CORP (US) | 2000-05-31 | — | — | EP | claimed |
| US-5922117-A | Ink compositions containing alcohols | XEROX CORPORATION (US) | 1999-07-13 | — | — | US | claimed |
| US-5663022-A | Recording sheets | XEROX CORPORATION (US) | 1997-09-02 | — | — | US | claimed |
| EP-0674232-A2 | Recording sheets | XEROX CORPORATION (US) | 1995-09-27 | — | — | EP | claimed |
| EP-0526537-A1 | 5-BENZYL BARBITURATE DERIVATIVES. | UNIV BROWN RES FOUND (US) | 1993-02-10 | — | — | EP | claimed |
| WO-1991016315-A1 | 5-BENZYL BARBITURATE DERIVATIVES | BROWN UNIVERSITY RESEARCH FOUNDATION (US) | 1991-10-31 | — | — | WO | claimed |
| EP-4663636-A2 | TRIFLUOROMETHYL SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS | BioCryst Pharmaceuticals, Inc. (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250270171-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-08-28 | — | — | US | disclosed |
| EP-4578856-A1 | HETEROCYCLIC COMPOUND | Ubience Inc. (JP) | 2025-07-02 | — | — | EP | disclosed |
| EP-4180424-B1 | SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS | BIOCRYST PHARM INC (US) | 2025-06-25 | — | — | EP | disclosed |
| US-4241081-A | Cyclopropanecarboxylate pesticides | SHELL OIL COMPANY (US) | 1980-12-23 | — | — | US | disclosed |
| US-4237123-A | INSECTICIDES, MITICIDES | SHELL OIL COMPANY (US) | 1980-12-02 | — | — | US | disclosed |
| US-4225612-A | Heterocyclic-substituted cyclopropanecarboxylate pesticides | SHELL OIL COMPANY (US) | 1980-09-30 | — | — | US | disclosed |
| US-4211792-A | Oxyimino-substituted (1R,trans)-cyclopropanecarboxylate pesticides | SHELL OIL COMPANY (US) | 1980-07-08 | — | — | US | disclosed |
| EP-0005882-A1 | A method of combating acarine pests by means of oxyimino-substituted cyclopropane-carboxylate esters, Z-isomers of certain such esters | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1979-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270171-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | CYP4F2 991/4885CYP4A11 690/4885TSHR 3844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.